Novo Nordisk is a publicly traded company trading on NYSE, led by CEO Maziar Mike Doustdar.
Upcoming earnings announcement for Novo Nordisk
Past 12 earnings reports for Novo Nordisk
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | Q4 2025 | $1.00Est: $0.89 | +12.4% | $12.3BEst: $12.1B | +2.1% | — |
| Nov 5, 2025 | Q3 2025 | $1.03Est: $0.77 | +33.4% | $11.7BEst: $11.9B | -1.1% | — |
| Aug 6, 2025 | Q2 2025 | $0.91Est: $0.93 | -2.2% | $11.7BEst: $11.8B | -0.9% | — |
| May 7, 2025 | Q1 2025 | $0.92Est: $0.90 | +2.2% | $10.9BEst: $11.6B | -6.4% | — |
| Feb 5, 2025 | Q4 2024 | $0.91Est: $0.83 | +9.6% | $12.3BEst: $11.3B | +8.1% | — |
| Nov 6, 2024 | Q3 2024 | $0.90Est: $0.88 | +2.3% | $10.5BEst: $10.5B | +0.1% | — |
| Aug 7, 2024 | Q2 2024 | $0.65Est: $0.69 | -5.8% | $9.8BEst: $10.0B | -1.5% | — |
| May 2, 2024 | Q1 2024 | $0.83Est: $0.74 | +12.2% | $9.5BEst: $9.1B | +4.9% | — |
| Jan 31, 2024 | Q4 2023 | $0.71Est: $0.65 | +9.1% | $9.5BEst: $8.8B | +7.8% | — |
| Nov 2, 2023 | Q3 2023 | $0.73Est: $0.71 | +2.8% | $8.6BEst: $7.9B | +8.4% | — |
| Aug 10, 2023 | Q2 2023 | $0.63Est: $0.64 | -1.6% | $7.9BEst: $8.0B | -0.4% | — |
| May 4, 2023 | Q1 2023 | $0.64Est: $0.64 | 0.0% | $7.7BEst: $7.7B | +0.5% | — |
We use cookies for analytics. See our Privacy and Cookie Policy.